These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21288053)

  • 1. Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.
    Ekesbo R; Sjöstedt S; Sörngård H
    Clin Drug Investig; 2011; 31(3):181-9. PubMed ID: 21288053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor.
    Jones R; Patrikios T
    Int J Clin Pract; 2008 Dec; 62(12):1844-50. PubMed ID: 19166433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
    Hoogendoorn RJ; Groeneveld L; Kwee JA
    Clin Drug Investig; 2009; 29(12):803-10. PubMed ID: 19888786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.
    Toghanian S; Johnson DA; Stålhammar NO; Zerbib F
    Clin Drug Investig; 2011 Oct; 31(10):703-15. PubMed ID: 21756007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical symptoms of GORD in Belgium: epidemiological features, current management and open label treatment with 40 mg esomeprazole for one month.
    Louis E; Jorissen P; Bastens B; D'Haens G; Schoofs N; Burette A; Christiaens P; Tack J;
    Acta Gastroenterol Belg; 2006; 69(2):203-8. PubMed ID: 16929616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients' burden of disease.
    Jones R; Horbach S; Sander P; Rydén-Bergsten T
    Pharmacoeconomics; 2003; 21(15):1091-102. PubMed ID: 14596628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of intensifying acid suppression on sleep disturbance related to gastro-oesophageal reflux disease in primary care.
    Moayyedi P; Hunt R; Armstrong D; Lei Y; Bukoski M; White R
    Aliment Pharmacol Ther; 2013 Apr; 37(7):730-7. PubMed ID: 23432146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.
    Kahrilas PJ; Jonsson A; Denison H; Wernersson B; Hughes N; Howden CW
    Gut; 2014 May; 63(5):720-6. PubMed ID: 23831734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.
    Thomson AB
    Clin Drug Investig; 2007; 27(10):663-72. PubMed ID: 17803341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
    Wilder-Smith C; Backlund A; Eckerwall G; Lind T; Fjellman M; Röhss K
    Clin Drug Investig; 2008; 28(6):333-43. PubMed ID: 18479175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
    Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
    Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GERD assessment including pH metry predicts a high response rate to PPI standard therapy.
    Kandulski A; Peitz U; Mönkemüller K; Neumann H; Weigt J; Malfertheiner P
    BMC Gastroenterol; 2013 Jan; 13():12. PubMed ID: 23324360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Sigterman KE; Bonis P; Lau J; Numans ME
    Cochrane Database Syst Rev; 2010 Nov; (11):CD002095. PubMed ID: 21069670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.
    Dent J; Vakil N; Jones R; Bytzer P; Schöning U; Halling K; Junghard O; Lind T
    Gut; 2010 Jun; 59(6):714-21. PubMed ID: 20551454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
    Orr WC
    Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):113-20. PubMed ID: 15647651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
    Johnson D; Crawley JA; Hwang C; Brown K
    Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland.
    Szucs T; Thalmann C; Michetti P; Beglinger C
    Value Health; 2009; 12(2):273-81. PubMed ID: 18783388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD002095. PubMed ID: 16855986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.